Advertisement

Topics

Schering Group Company Profile

10:55 EDT 20th June 2018 | BioPortfolio

Responsible, sustainable business practices are a clear objective for Schering. While this means integrating ecological aspects, it also means fulfilling the growing expectations of many people with regard to social values, whilst balancing these with economic sustainability for our company. The challenge is to consider economic, ecological and social decisions on an equal basis as well as to put them into practice alongside each other.

Location

Muellerstr. 178
Berlin
13353
Germany

Contact

Phone: 49-30-468-11 11
Fax: 49-30-468-15305
Email: bDSB@schering.de


News Articles [393 Associated News Articles listed on BioPortfolio]

Bayer Schering Pharma: Michael Yeomans on Growth in Pharma and New Deals

In this episode of PharmaTelevision News Review, Fintan Walton talks with Michael Yeomans, VP Business Development & Licensing at Bayer Schering Pharma*. Filmed at BioChicago 2010 in Chicago, USA, the...

Merck & Co.: Merging With Schering-Plough and Future Plans

In this episode of PharmaTelevision News Review, Fintan Walton talks with Pamela Demain, Executive Director, Corporate Licensing at Merck & Co. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, th...

Astellas promotes Anthony Fiordaliso to VP, Americas finance

He first joined the pharma firm in 2010 from Schering-Plough

PTV News: Nov 5, 2009

Top stories on November 5th, 2009: Merck complete Schering-Plough merger Novartis buys Chinese vaccine maker BioPad’s Joe Mosala Molete on South African biotech Pfizer on partnering: Doug Giordan...

CEO Blog: Social Media Enhances My Interactions with Customers

By Brent Saunders, CEO, Allergan As a young executive at Schering-Plough, I learned a lot from Fred Hassan about the importance of ‘Being Connected’ and ‘Tuning In’ to customers by spendin...

Unlimited Group appoints group managing director

Michael Richards joins the group from VCCP

TMX Group Limited Declares Dividend of $0.50 per Common Share

For the results of the quarter ended December 31, 2017for TMX Group, please click on the following link: http://www.tmx.com/investor-relations/ About TMX Group (TSX:X) TMX Read more...

The New Merck

In recent years, Merck & Co.'s corporate strategy has included a significant amount of licensing and partnering in order to externalise their pipeline and ensure that the company gets access to the be...

PubMed Articles [1815 Associated PubMed Articles listed on BioPortfolio]

Group Influences on Engaging Self-Control: Children Delay Gratification and Value It More When Their In-Group Delays and Their Out-Group Doesn't.

Self-control emerges in a rich sociocultural context. Do group norms around self-control influence the degree to which children use it? We tested this possibility by assigning 3- to 5-year-old childre...

An Examination of Group Size and Valence in Delay Discounting of Shared Outcomes.

Previous research has examined delay discounting in a group context, where the outcomes are shared with others. These studies indicate shallow delay discounting in a group context compared to an indiv...

Ameliorating effects of tempol on methotrexate-induced liver injury in rats.

Methotrexate (MTX) is used in the treatment of certain types of cancers and chronic inflammatory illnesses, although the clinical use of MTX is limited due to its adverse effects, the most common of w...

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Gro...

Nephroprotective Effect of Zingerone against CCl-Induced Renal Toxicity in Swiss Albino Mice: Molecular Mechanism.

The protective effects of Zingerone against CCl induced nephrotoxicity in Swiss albino mice via modulation of metabolizing enzyme, oxidative stress, inflammatory cytokines, and apoptosis. The biochemi...

Clinical Trials [3713 Associated Clinical Trials listed on BioPortfolio]

Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis

The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (lor...

Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets

The present study was a randomized, open-label, two-period, two-sequence, cross-over study, conducted to find out whether the etoricoxib 120 mg film-coated tablet produced by PT Dexa Medic...

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Aim: to observe the graft versus tumor effect of Pegylated Interferonα-2b in patients with hematological malignancies relapsed after allogeneic hematopoietic stem cell transplantation (al...

Remicade Infusion Management Program (Study P04466)

Schering Canada plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infu...

Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions

To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with Claritin® Re...

Companies [1653 Associated Companies listed on BioPortfolio]

Schering Health Care Limited

Schering Health Care is the UK subsidiary of Schering AG, an international pharmaceutical company with headquarters located in Berlin, Germany.Schering is a global company, with over 150 subsidiaries ...

Schering-Plough Corp.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies th...

Schering Group

Responsible, sustainable business practices are a clear objective for Schering. While this means integrating ecological aspects, it also means fulfilling the growing expectations of many people with r...

Intervet/Schering-Plough Animal Health

Intervet/Schering-Plough Animal Health, based in Boxmeer, the Netherlands, is focused on the research, development, manufacturing and marketing of animal health products. The company offers customers ...

Schering-Plough

Schering-Plough is committed to earning the trust of doctors, patients and customers every day. Our colleagues worldwide believe that trust is not easily granted, and that is the reason we focus each ...

More Information about "Schering Group" on BioPortfolio

We have published hundreds of Schering Group news stories on BioPortfolio along with dozens of Schering Group Clinical Trials and PubMed Articles about Schering Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Schering Group Companies in our database. You can also find out about relevant Schering Group Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record